These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1615333)

  • 41. Erythropoietin--improving the quality of life of dialysis patients.
    Kionka C
    J Biotechnol; 1995 Nov; 43(1):73-4. PubMed ID: 8573324
    [No Abstract]   [Full Text] [Related]  

  • 42. Management of anemia in oncology. Introduction.
    Adamson JW
    Semin Oncol; 1992 Jun; 19(3 Suppl 8):1-2. PubMed ID: 1615333
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
    Fandrey JK; Jelkmann WE
    Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin].
    Adam Z; Krejcí M; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):285-9. PubMed ID: 8693717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The adverse effects of recombinant human erythropoietin therapy.
    Wong KC; Li PK; Lui SF; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(4):183-206. PubMed ID: 2088088
    [No Abstract]   [Full Text] [Related]  

  • 47. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant human erythropoietin. Experimental and clinical applications.
    Nielsen OJ
    Dan Med Bull; 1991 Oct; 38(5):355-70. PubMed ID: 1802621
    [No Abstract]   [Full Text] [Related]  

  • 49. [The significance of erythropoietin for nephrology].
    Watzinger U; Peer G; Barnas U; Mayer G; Luger A; Kovarik J; Graf H
    Wien Klin Wochenschr; 1990 Mar; 102(5):125-30. PubMed ID: 2181782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical spectrum of iron overload, novel uses of iron chelators, and potential treatment of pediatric anemias with erythropoietin. Introduction.
    Cairo MS
    Am J Pediatr Hematol Oncol; 1990; 12(1):1-3. PubMed ID: 2178456
    [No Abstract]   [Full Text] [Related]  

  • 51. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythropoietin 1991--an overview.
    Eschbach JW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of recombinant human erythropoietin [rHuEpo] in man.
    Adamson JW; Eschbach JW
    Prog Clin Biol Res; 1990; 352():505-17. PubMed ID: 2205875
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.